A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing ...

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly ...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple ...

Abstract #S230.) Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients with Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of ...

Investing.com -- Shares of Incyte (NASDAQ: INCY) climbed 7% today after the biopharmaceutical company announced that multiple ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r - - Axatilimab abstracts ...

Poster presentations will cover a range of topics, such as the Phase 3 study of Axatilimab for chronic graft-versus-host disease and the efficacy of the BET protein inhibitor INCB057643 in myeloid ...

“The data being presented at EHA showcase the potential for revumenib and axatilimab to transform the treatment paradigm for patients with acute leukemia and chronic GVHD, respectively,” said ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...